Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB et al (2017) Biomarker-driven phenotyping in Parkinson’s disease: a translational missing link in disease-modifying clinical trials. Mov Disord 32:319–324

Article  PubMed  PubMed Central  Google Scholar 

Fereshtehnejad S-M, Romenets SR, Anang JBM, Latreille V, Gagnon J-F, Postuma RB (2015) New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 72:863–873

Article  PubMed  Google Scholar 

Pilotto A, di Schiano Cola F, Premi E, Grasso R, Turrone R, Gipponi S et al (2019) Extrastriatal dopaminergic and serotonergic pathways in Parkinson’s disease and in dementia with Lewy bodies: a 123 I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 46:1642–51

Article  CAS  PubMed  Google Scholar 

Markello RD, Arnatkeviciute A, Poline J-B, Fulcher BD, Fornito A, Misic B (2021) Standardizing workflows in imaging transcriptomics with the abagen toolbox. Elife 10:e72129

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boylan LS, Chiò A (2019) Divining progression in Parkinson disease with a blood test: NfL. Neurology 93(11):471–472

Article  PubMed  Google Scholar 

Pilotto A, Imarisio A, Conforti F, Scalvini A, Masciocchi S, Nocivelli S et al (2021) Plasma NfL, clinical subtypes and motor progression in Parkinson’s disease. Parkinsonism Relat Disord 87:41–47

Article  CAS  PubMed  Google Scholar 

Lin C-H, Li C-H, Yang K-C, Lin F-J, Wu C-C, Chieh J-J et al (2019) Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 93:e1104–e1111

Article  CAS  PubMed  Google Scholar 

van Rumund A, Aerts MB, Esselink RAJ, Meijer FJA, Verbeek MM, Bloem BR (2018) Parkinson’s Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism. BMC Neurol 18:1–7

Google Scholar 

Bartl M, Dakna M, Galasko D, Hutten SJ, Foroud T, Quan M et al (2021) Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease. PLoS One 16:e0257372

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benedet AL, Milà-Alomà M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F et al (2021) Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol 78:1471–1483

Article  PubMed  Google Scholar 

Bolsewig K, van Unnik AAJM, Blujdea ER, Gonzalez MC, Ashton NJ, Aarsland D et al (2024) Association of plasma amyloid, p-Tau, GFAP, and NfL with CSF, clinical, and cognitive features in patients with dementia with lewy bodies. Neurology 102(12):e209418

Article  PubMed  PubMed Central  Google Scholar 

Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E et al (2016) Plasma tau in Alzheimer disease. Neurology 87:1827–1835

Article  CAS  PubMed  PubMed Central  Google Scholar 

Milà-Alomà M, Ashton NJ, Shekari M, Salvadó G, Ortiz-Romero P, Montoliu-Gaya L et al (2022) Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease. Nat Med 28:1797–1801

PubMed  PubMed Central  Google Scholar 

Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G et al (2021) Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology. Acta Neuropathol 141:709–724

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hall S, Janelidze S, Londos E, Leuzy A, Stomrud E, Dage JL et al (2021) Plasma Phospho-tau identifies Alzheimer’s co-pathology in patients with Lewy body disease. Mov Disord 36:767–771

Article  CAS  PubMed  Google Scholar 

Pilotto A, Parigi M, Bonzi G, Battaglio B, Ferrari E, Mensi L et al (2022) Differences between plasma and cerebrospinal fluid p-tau181 and p-tau231 in early Alzheimer’s disease. J Alzheimer’s Dis 87:991–997

Article  CAS  Google Scholar 

Gonzalez-Ortiz F, Kac PR, Brum WS, Zetterberg H, Blennow K, and Karikari TK (2023) Plasma phospho-tau in Alzheimer’s disease: toward diagnostic and therapeutic trial applications. In molecular neurodegeneration (Vol. 18, Issue 1). BioMed Central Ltd

Vrillon A, Bousiges O, Götze K, Demuynck C, Muller C, Ravier A et al (2024) (2024) Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies. Alzheimers Res Ther 16(1):146

Article  CAS  PubMed  PubMed Central  Google Scholar 

Postuma RB, Berg D, Stern M, Poewe W, Marek K, Litvan I (2015) CME MDS clinical diagnostic criteria for Parkinson’s disease centrality of motor syndrome—Parkinsonism and PD criteria benchmark—the expert examination. Mov Disord 30(12):1591–1601

Article  PubMed  Google Scholar 

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord 25:2649–2653

Article  PubMed  Google Scholar 

Berg D, Adler CH, Bloem BR, Chan P, Gasser T, Goetz CG et al (2018) Movement disorder society criteria for clinically established early Parkinson’s disease. Mov Disord 33:1643–1646

Article  PubMed  Google Scholar 

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170

Article  PubMed  Google Scholar 

Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C et al (2004) Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 19:1020–1028

Article  PubMed  Google Scholar 

Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V et al (2018) High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature 554:249–254

Article  CAS  PubMed  Google Scholar 

Chiu P-Y, Yang F-C, Chiu M-J, Lin W-C, Lu C-H, Yang S-Y (2022) Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia. Sci Rep 12:17919

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gonzalez MC, Ashton NJ, Gomes BF, Tovar-Rios DA, Blanc F, Karikari TK et al (2022) Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with lewy bodies. JAMA Neurol 79:32–37

Article  PubMed  Google Scholar 

Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E et al (2022) Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 93:651–658

Article  PubMed  Google Scholar 

Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C et al (2010) CSF amyloid-β and tau proteins, and cognitive performance, in early and untreated Parkinson’s Disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 81(10):1080–1086

Article  PubMed  Google Scholar 

Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P et al (2015) CSF tau and tau/Aβ42 predict cognitive decline in Parkinson’s disease. Parkinsonism Relat Disord 21:271–276

Article  PubMed  PubMed Central  Google Scholar 

Abdelnour C, Ferreira D, Oppedal K, Cavallin L, Bousiges O, Wahlund LO et al (2020) The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies. Neuroimage Clin 27:102333

Article  PubMed  PubMed Central  Google Scholar 

Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM (2017) Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson’s disease: a cohort study. Lancet Neurol 16:66–75

Article  CAS  PubMed  Google Scholar 

Terrelonge M, Marder KS, Weintraub D, Alcalay RN (2016) CSF β-amyloid 1–42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. J Mol Neurosci 58:88–92